Lasa Supergenerics Ltd
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
- Market Cap ₹ 47.8 Cr.
- Current Price ₹ 9.54
- High / Low ₹ 31.4 / 8.16
- Stock P/E 99.6
- Book Value ₹ 11.2
- Dividend Yield 0.00 %
- ROCE -1.00 %
- ROE 1.01 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.85 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.16% over past five years.
- Company has a low return on equity of -9.72% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2016 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 95 | |
| 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 96 | |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | -1 |
| OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 2% | 4% | -1% | |
| 0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -33 | |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 1 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 10 |
| Profit before tax | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -44 |
| Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | ||
| 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -36 | |
| EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -2.95 | -7.22 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | 1% |
| TTM: | -20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -28% |
| TTM: | 103% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -35% |
| 3 Years: | -35% |
| 1 Year: | -65% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 6 |
| 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 7 | |
| 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 8 | |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
| 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 58 | |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 13 | |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
Cash Flows
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | -3 | 40 | 41 | 14 | 41 | 9 | -17 | 2 | -3 | |
| 0 | 0 | -44 | -7 | -2 | -4 | -3 | 11 | -0 | 8 | |
| 0 | 0 | 4 | -33 | -10 | -36 | -0 | -4 | -2 | -6 | |
| Net Cash Flow | 0 | -3 | 0 | -0 | 2 | 1 | 6 | -10 | -0 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | |
| Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | |
| Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | |
| Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | |
| Working Capital Days | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | |
| ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Cessation
1d - Whole-time Director Prathmesh Chalke resigns effective closing hours 31 December 2025; resignation dated 11 December 2025.
-
Related Party Trasnaction As 30.09.2025
14 Nov - Related-party transaction disclosure for quarter/half-year ended Sep 30, 2025; lists payments (total 710) and donations (28.50).
-
Integrated Filing September 30 ,2025
14 Nov - Board approved Q2 results; uninsured May 18, 2025 fire caused Rs1,273.62L inventory, Rs700L PPE losses; operations halted.
- Results As On 30 Th Septemer 2025 14 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting For The Quarter Ended 30 September, 2025
14 Nov - Approved Q2/H1 results; uninsured fire losses ~Rs2,057.47 lakh; operations suspended.
Annual reports
Concalls
-
Aug 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptAI SummaryPPT
-
Jun 2020Transcript PPT
-
Jun 2018Transcript PPT
-
Feb 2018TranscriptAI SummaryPPT
-
Dec 2017Transcript PPT
Business Overview:[1]
LSL is a part of Lasa group which is a veterinary API manufacturing entity. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary APIs with one of the largest production capabilities in India. It covers entire animal and human healthcare value chain—from discovery-to-delivery, in research, manufacturing and global marketing. Company has backward integrated its key molecules—from discovery research up to full-scale bulk production